Radiation Oncology & Cancer Metabolism Laboratory

Decoding how cancer rewires its metabolism, its microenvironment, and its response to radiation.

Yu-Chan ChangPh.D., FHEA張 御 展

Associate Professor · since August 2024
國立陽明交通大學 生物醫學工程學院 生物醫學影像暨放射學系 Department of Biomedical Imaging and Radiological Sciences, College of Biomedical Science and Engineering, National Yang Ming Chiao Tung University (NYCU)

Our laboratory studies how adaptive metabolic reprogramming shapes the cancer transcriptome and proteome during metastasis and therapy resistance, with a parallel translational focus on the mechanisms driving lung, breast, brain, and hepatobiliary–pancreatic malignancies. We also provide translational pathology support to colleagues across NYCU and Taipei Veterans General Hospital.

Yu-Chan Chang, Ph.D.
Principal Investigator
Top 2% Scientist badge, TOPSCINET, 2026
89Publications listed
56Abstracts & invited talks
18Funded projects
~150Manuscripts reviewed · BBA-MBD
01

Selected Works

i
Therapy resistance · Radiobiology

Targeting ESR1 restores SQSTM1-dependent autophagy and sensitizes ER-positive breast cancer to oxidative and radiation stress

Cell Death Discovery · 2025
ii
Tumor microenvironment

Comparative impact of tertiary lymphoid structures and tumor-infiltrating lymphocytes in cholangiocarcinoma

Journal for ImmunoTherapy of Cancer · 2025
iii
Metabolic reprogramming

PPAR-γ agonists reactivate the ALDOC–NR2F1 axis to enhance sensitivity to temozolomide and suppress glioblastoma progression

Cell Communication and Signaling · 2024
iv
Metabolism · Macrophage polarization

ALDOA coordinates PDE3A through the β-catenin/ID3 axis to stimulate metastasis and M2 polarization in EGFR-mutant lung cancer

Biochem Biophys Res Commun · 2024
v
Immuno-oncology · Biomarkers

The correlation between LAG-3 expression and the efficacy of chemoimmunotherapy in advanced biliary tract cancer

Cancer Immunology, Immunotherapy · 2025
vi
Review · Tumor microenvironment

Multiverse of phosphoglycerate kinase: canonical, moonlighting, and tumor microenvironmental functions

BBA — Molecular Basis of Disease · 2026
02

Research Focus

Cancer–Macrophage Crosstalk

Tumor microenvironment remodeling through macrophage secretomes and polarization states, and how these signals feed back into tumor cell behavior and immune evasion.

TME · Macrophage Polarization

Metabolic Reprogramming in Cancer

Non-enzymatic and enzymatic roles of aldolase isoforms (ALDOA/ALDOC/ALDOB), the VHL–glycolysis axis, purine/pyrimidine biosynthesis, and lactylation-driven epigenetic regulation in tumor progression.

ALDOA · VHL · Glycolysis

Radiobiology & Translational Pathology

Cellular imaging and histomorphological approaches to radiation response, ferroptosis, and immune infiltration, applied to glioblastoma, cholangiocarcinoma, and renal cell carcinoma.

Radiobiology · Cellular Imaging

The Research Island

Seven research themes arranged as a radiation trefoil — every building a project, paper or program, every golden arc a collaboration. Explore the lab as a map.

Enter the island →
03

Lab Philosophy

i

Rigor

Every claim traced to a clean experiment, a proper control and a reproducible figure — before it reaches a manuscript.

ii

Curiosity

We follow metabolism wherever it leads: from a single enzyme to the microenvironment, and from the bench to the patient's pathology slide.

iii

Mentorship

Training scientists is the lab's longest-lasting output. Students and visitors are given real questions, real ownership and real credit.

04

Positions & Education

Academic & Research Positions

2024–present
Associate Professor
Dept. of Biomedical Imaging and Radiological Science, NYCU
2021–2024
Adjunct Assistant Professor
Institute of Pathology and Parasitology, National Defense Medical Center
2020–2024
Assistant Professor
Dept. of Biomedical Imaging and Radiological Science, NYCU
2017–2020
Postdoctoral Fellow
Genomics Research Center, Academia Sinica, Taipei

Education

2011–2017
Ph.D., Life Sciences
National Defense Medical Center, Taipei
2009–2011
M.S., Dentistry
National Defense Medical Center, Taipei
2005–2009
B.S., Dental Hygiene
China Medical University, Taichung
05

Research Grants

2026
VGHUST115-G3-1-2
The m6A modification in the development and progression of renal cell carcinoma PI
2026
CI-115-17
Fructose metabolism and ferroptosis modulated by ALDOB in colorectal cancer microsatellite instability PI
2026
CY115-11406
Multi-omics integration, predictor identification and tumor microenvironment construction in advanced renal cell carcinoma PI
2025–2028
NSTC 114-2314-B-A49-0253-MY3
ALDOA reprograms cancer metabolism, macrophage polarization and cancer immunity through epigenetic lactylation in lung cancer PI
2025
VGHUST114-G1-8-3
Interpretation of the relationship between NRF2, ROS and ferroptosis regulated by SLC25A11 PI
2025
CY11406
Multi-omics integration, predictor identification and tumor microenvironment construction in advanced renal cell carcinoma PI
2024
NYCUKMU-113-I0023
Patient-derived organoid/xenograft models as therapeutic strategies for Osimertinib-resistant lung cancer PI
2023–2026
NSTC 112-2314-B-075-021-MY3
Influence of IDH1 hotspot mutations on cellular and tumor microenvironment in cholangiocarcinoma Co-PI
2023–2026
NSTC 112-2314-B-075-009-MY3
Role of B cells and tertiary lymphoid structures (TLS) in the tumor microenvironment of cholangiocarcinoma Co-PI
2023
NYCUKMU-112-I003
Precision medicine prediction and novel strategies for third-generation EGFR-TKI resistant lung cancer PI
2023
CI-112-6
Aldolase A degrades ATPase inhibitory factor and reprograms energy metabolism in cancer stem cells PI
2022–2025
MOST 111-2314-B-A49-036-MY3
Therapeutic effect, immune infiltration and IDH1 mutation of ALDOC/PPAR-γ signaling in glioblastoma PI
2022
111-2813-C-A49-111-B
Pyrimidine biosynthesis in urothelial carcinomas and its relationship with the FGFR family PI
2022
VGHUST111-G3-3-2
Purine biosynthesis in urothelial carcinomas and its relationship with the FGFR family PI
2022
CI-111-9
Aldolase A and Phospholipase D1 synergy promoting autophagy/DNA repair against alkylating agents and radiation in lung cancer PI
2021–2022
MOST 110-2320-B-010-008-MY2
ALDOC regulates PPAR-γ signaling and serotonin to inhibit glioblastoma PI
2017–2020
MOST 107-2320-B-001-016-MY3
Molecular mechanisms of Aldolase A non-enzymatic function-induced lung cancer stemness and chemoresistance PI: M. Hsiao
2016–2019
MOST 106-2320-B-038-035-MY3
Molecular mechanisms of secretory RAB GTPase 3C in promoting colon cancer metastasis PI: C.L. Chen
06

Honors & Awards

07

Rankings & Impact

Stanford University / Elsevier

World's Top 2% Scientists

Single-year impact list, 2026 — Clinical Medicine · Oncology & Carcinogenesis.

View profile →
ScholarGPS® Ranking Analytics · 2026

Top 0.09% in Cancer

h-index rank 462 among 800,382 scholars in the specialty (top 0.09%); Quality top 0.13%, Impact top 0.18%. Life Sciences: top 0.36% for Quality.

Field: Life Sciences · Discipline: Biochemistry
101Total publications
3,621Total predicted citations
36Predicted h-index (all fields)
ScopeScholars rankedProductivityrank · top %Impact (citations)rank · top %h-indexrank · top %Qualityrank · top %
Overall (All Fields)9,375,746199,5652.13%61,3560.65%33,5870.49%58,7400.63%
Life Sciences1,144,60612,2251.07%5,4210.47%2,3430.3%4,0860.36%
Biochemistry83,3087130.86%3070.37%1210.21%2350.28%
Specialties
Cancer800,3825,1100.64%1,4530.18%4620.09%1,0570.13%
Lung cancer119,0736,5385.49%1,6231.36%1,2963.45%2,3912.01%
Glioblastoma42,6452,0434.79%1,3773.23%3683.06%9512.23%
Metastasis102,4541,8611.82%3,8743.78%2,98521.28%2,9492.88%
Colorectal cancer126,6809,7517.7%9,8847.8%7,12325.76%10,0927.97%
Biosensor49,4504,0538.31%2,0244.09%1,6287.43%2,3124.68%
Magnetic resonance imaging144,46014,0799.82%4,1722.89%1,1272.62%4,2782.96%
Cell death68,9918861.28%3,4234.96%3312.18%8071.17%
Biomarker259,37715,2845.99%2,7651.07%9121.58%2,9641.14%
Platinum nanoparticle2,694572.15%1154.27%10.91%240.87%
Protein448,30544,74210.01%50,77611.38%4,6332.97%21,1014.71%
Neoplasm398,79874,07018.58%2,3670.59%21,21324.14%17,5424.4%
Cancer immunotherapy62,4227,68912.34%22,83236.58%3,56828.21%11,19717.94%
Cancer cell115,17332,76928.51%40,93735.59%4,80629.08%33,19928.82%
Squamous cell carcinoma63,18123,23239.85%10,28516.31%1,95819.98%12,76520.22%

Source: ScholarGPS® Ranking Analytics, 2026. Evaluation period: prior 5 years; citation counts exclude self-citations; author weighting: weighted. “Top %” is the percentile among scholars ranked in the same scope. Productivity = weighted publications; Impact = weighted citations; Quality = composite Z score.

08

Lab News & Milestones

2026

11.05
ScholarGPS® 2026 ranking: top 0.09% in the Cancer specialty by h-index (top 0.13% Quality, top 0.18% Impact); top 0.36% in Life Sciences for Quality.
10.11
Yu-Chan Chang named to the World's Top 2% Scientists list (Single-Year Impact, 2026), Stanford University / Elsevier — Clinical Medicine, Oncology & Carcinogenesis.
09.23
Yu-Chan Chang receives the NYCU 114學年度優良教學教師獎 (Outstanding Teaching Award), presented by President Chi-Hung Lin.
09.22
Invited speaker, 創新醫材轉譯研發工作坊系列-4「標靶α治療與精準癌症治療工作坊」(Targeted Alpha Therapy and Precision Cancer Treatment Workshop), NYCU College of Biomedical Science and Engineering.
08.28
Yu-Chan Chang awarded the 2026 黃忠山學術論文獎.
06.06
First place, Basic/Translational Medicine poster session, 23rd VGH–Taiwan University System Joint Research Symposium.
06.04
PhD students Yu-Yu Lin (merit award) and Chao-Ching Ho (distinction) recognized at the 2026 academic thesis symposium, doctoral track.
06.01
Yu-Chan Chang achieves UK Fellowship of the Higher Education Academy (FHEA).
05.14
PhD student Chao-Ching Ho: Outstanding Poster Award, 2026 International Metabolic Medicine Conference; finalist for oral presentation, 5th Merck Young Scientist Award.
03.21
Invited speaker, 40th Annual Meeting; PhD student Chao-Ching Ho — 3rd place poster, Molecular Imaging Society.
03.10
Yu-Chan Chang completes the Oxford EMI Training Programme.
Show earlier milestones (2021–2025)

2025

11.15
Invited speaker, Central Taiwan Cholangiocarcinoma Symposium.
11.01
Invited speaker, 2025 AACR Campus on Taiwan.
09.01
PhD students Yu-Yu Lin / Chao-Ching Ho awarded MOE Doctoral Research Fellowships.
08.01
Chao-Ching Ho admitted to direct PhD track, Dept. of BIRS, NYCU.
08.01
Yu-Yu Lin admitted to PhD program, Dept. of BIRS, NYCU.
05.17
Yu-Yu Lin: Merit Award, Merck Young Scientist Award (Cancer Immunology).
03.29
Yu-Chan Chang receives 114年台北市社會優秀青年.
03.23
Yu-Yu Lin: 3rd place poster, Molecular Imaging Society, 39th Annual Meeting.
02.24
Yu-Chan Chang receives the IJMS Young Investigator Award (2024).

2024

11.29
Participated in the Chiayi regional 113學年度協作共好計畫.
11.20
Participated in a high-school advisory forum on learning-portfolio alignment with university admissions.
10.11
Invited talk at Taichung Hsiao Ming Girls' High School: "Seeing is Believing — Cells at Work."
09.01
Han-Hsi Kuo receives NSTC Doctoral Research Fellowship.
08.01
Han-Hsi Kuo admitted to PhD program, Dept. of BIRS, NYCU.
05–06
MS students Chia-Ying Yeh and Han-Hsi Kuo: Merck Young Scientist Award finalists; academic symposium merit/distinction awards.
03.23–24
38th Biomedical Annual Meeting — Molecular Imaging Society: Han-Hsi Kuo, 1st place poster; Chia-Ying Yeh, oral distinction.
01–03
Hosted IIPP visiting students Thomas and Jade (Hanoi University of Pharmacy).

2021–2023

2023
Po-Hsuan Lin (MS): oral presentation and poster awards at the 37th annual meeting; Merck Young Scientist Award finalist and New Star Award; academic symposium distinction. Yu-Chan Chang receives the 2023 college English-medium-instruction teaching award and 3rd place, clinical medicine poster, 19th VGH–UST Symposium.
2022
Chao-Ching Ho (undergraduate) receives Platinum Technology Outstanding Student Award (two consecutive terms). Yu-Chan Chang receives the Shen Li-Yang Memorial Foundation medical education grant.
2021
Yu-Chan Chang receives the MOST Young Scholar Fellowship for outstanding early-career recruitment.
09

Lab Members

PhD Students

Han-Hsi Kuo
Han-Hsi Kuo
郭翰錫 · entered 2024
Yu-Yu Lin
Yu-Yu Lin
林又妤 · entered 2025
Chao-Ching Ho
Chao-Ching Ho
何兆璟 · entered 2025, direct-PhD

MS Students

Hsiang-Yu Cheng
Hsiang-Yu Cheng
鄭翔友 · 2025
Ching-Ho Chao
Ching-Ho Chao
趙菁禾 · 2025
Yi-Chieh Sung
Yi-Chieh Sung
宋裔婕 · 2026
Ying-Yu Wu
Ying-Yu Wu
吳映瑜 · 2026

Graduated Members

Chia-Ying Yeh
Chia-Ying Yeh
MS · graduated 2024
Huei-Yu Cai
Huei-Yu Cai
蔡惠宇 · MS · graduated 2023
Po-Hsuan Lin
Po-Hsuan Lin
MS · graduated 2023

Undergraduate & Visiting

Chao-Ching Ho
Chao-Ching Ho
何兆璟 · MOST program
HC
Hsiao-Chen Cheng
鄭筱臻
Phạm Hưng Thịnh (Thomas)
Phạm Hưng Thịnh
(Thomas) · Hanoi Univ. of Pharmacy · IIPP 2024
Phí Ngọc Trâm (Jade)
Phí Ngọc Trâm
(Jade) · Hanoi Univ. of Pharmacy · IIPP 2024
Veronica Kuo
Veronica Kuo
Univ. of Southern California · IIPP 2024